|
Name |
(2R)-6-[(1E,3E,5E)-6-[(2R,3R,3aR,4R,5R,6aR)-2-ethyl-3,4-dihydroxy-3,3a-dimethyl-2,4,5,6a-tetrahydrofuro[2,3-b]furan-5-yl]hexa-1,3,5-trienyl]-2,3,3,7-tetramethyl-2H-furo[3,2-c]pyran-4-one
|
| Molecular Formula | C27H36O7 | |
| IUPAC Name* |
(2R)-6-[(1E,3E,5E)-6-[(2R,3R,3aR,4R,5R,6aR)-2-ethyl-3,4-dihydroxy-3,3a-dimethyl-2,4,5,6a-tetrahydrofuro[2,3-b]furan-5-yl]hexa-1,3,5-trienyl]-2,3,3,7-tetramethyl-2H-furo[3,2-c]pyran-4-one
|
|
| SMILES |
CC[C@@H]1[C@]([C@]2([C@H]([C@H](O[C@@H]2O1)/C=C/C=C/C=C/C3=C(C4=C(C(=O)O3)C([C@H](O4)C)(C)C)C)O)C)(C)O
|
|
| InChI |
InChI=1S/C27H36O7/c1-8-19-27(7,30)26(6)22(28)18(33-24(26)34-19)14-12-10-9-11-13-17-15(2)21-20(23(29)32-17)25(4,5)16(3)31-21/h9-14,16,18-19,22,24,28,30H,8H2,1-7H3/b10-9+,13-11+,14-12+/t16-,18-,19-,22+,24-,26+,27+/m1/s1
|
|
| InChIKey |
XEVKZSAFNVBSSK-JKWMLAQSSA-N
|
|
| Synonyms |
Avertoxin D; J3.513.369K
|
|
| CAS | NA | |
| PubChem CID | 132605275 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 472.6 | ALogp: | 3.5 |
| HBD: | 2 | HBA: | 7 |
| Rotatable Bonds: | 5 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 94.4 | Aromatic Rings: | 4 |
| Heavy Atoms: | 34 | QED Weighted: | 0.611 |
| Caco-2 Permeability: | -4.895 | MDCK Permeability: | 0.00001100 |
| Pgp-inhibitor: | 0.132 | Pgp-substrate: | 0.764 |
| Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.002 |
| 30% Bioavailability (F30%): | 0.005 |
| Blood-Brain-Barrier Penetration (BBB): | 0.051 | Plasma Protein Binding (PPB): | 87.67% |
| Volume Distribution (VD): | 1.347 | Fu: | 6.07% |
| CYP1A2-inhibitor: | 0.242 | CYP1A2-substrate: | 0.69 |
| CYP2C19-inhibitor: | 0.612 | CYP2C19-substrate: | 0.779 |
| CYP2C9-inhibitor: | 0.872 | CYP2C9-substrate: | 0.958 |
| CYP2D6-inhibitor: | 0.828 | CYP2D6-substrate: | 0.864 |
| CYP3A4-inhibitor: | 0.784 | CYP3A4-substrate: | 0.868 |
| Clearance (CL): | 1.538 | Half-life (T1/2): | 0.257 |
| hERG Blockers: | 0.267 | Human Hepatotoxicity (H-HT): | 0.988 |
| Drug-inuced Liver Injury (DILI): | 0.96 | AMES Toxicity: | 0.558 |
| Rat Oral Acute Toxicity: | 0.808 | Maximum Recommended Daily Dose: | 0.951 |
| Skin Sensitization: | 0.566 | Carcinogencity: | 0.017 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.017 |
| Respiratory Toxicity: | 0.401 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC001850 | ![]() |
0.657 | D04JMQ | ![]() |
0.214 | ||
| ENC005399 | ![]() |
0.609 | D02YIZ | ![]() |
0.210 | ||
| ENC005400 | ![]() |
0.569 | D0Z1ZM | ![]() |
0.206 | ||
| ENC005994 | ![]() |
0.395 | D03HJK | ![]() |
0.200 | ||
| ENC003144 | ![]() |
0.373 | D0W2EK | ![]() |
0.200 | ||
| ENC005401 | ![]() |
0.371 | D0E9KA | ![]() |
0.200 | ||
| ENC005765 | ![]() |
0.359 | D0TG7I | ![]() |
0.197 | ||
| ENC005764 | ![]() |
0.359 | D0FG6M | ![]() |
0.188 | ||
| ENC003250 | ![]() |
0.247 | D06ZUP | ![]() |
0.188 | ||
| ENC004533 | ![]() |
0.241 | D0H2MO | ![]() |
0.184 | ||